Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 157

Similar articles for PubMed (Select 23291985)

1.

Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice.

Nishikawa T, Takaoka M, Ohara T, Tomono Y, Hao H, Bao X, Fukazawa T, Wang Z, Sakurama K, Fujiwara Y, Motoki T, Shirakawa Y, Yamatsuji T, Tanaka N, Fujiwara T, Naomoto Y.

Cancer Biol Ther. 2013 Mar;14(3):230-6. doi: 10.4161/cbt.23294. Epub 2013 Jan 4.

2.

Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells.

Ohara T, Takaoka M, Toyooka S, Tomono Y, Nishikawa T, Shirakawa Y, Yamatsuji T, Tanaka N, Fujiwara T, Naomoto Y.

Cancer Sci. 2011 Jul;102(7):1344-9. doi: 10.1111/j.1349-7006.2011.01967.x. Epub 2011 Jun 2.

PMID:
21521416
3.

Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.

Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.

Biochem Pharmacol. 2012 May 1;83(9):1146-58. doi: 10.1016/j.bcp.2012.01.013. Epub 2012 Jan 20.

PMID:
22285225
4.
5.

Novel HSP90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma.

Okui T, Shimo T, Fukazawa T, Mohammad Monsur Hassan N, Honami T, Ibaragi S, Takaoka M, Naomoto Y, Sasaki A.

Curr Cancer Drug Targets. 2013 Mar;13(3):289-99.

PMID:
23016912
6.

SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.

Gen Y, Yasui K, Nishikawa T, Yoshikawa T.

Cancer Sci. 2013 Jul;104(7):810-6. doi: 10.1111/cas.12155. Epub 2013 Apr 16.

PMID:
23510069
7.

A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.

Huang Y, Xi Q, Chen Y, Wang J, Peng P, Xia S, Yu S.

Anticancer Drugs. 2013 Oct;24(9):889-98. doi: 10.1097/CAD.0b013e328363c64e.

PMID:
23838676
8.

Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.

Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M.

Neoplasia. 2012 Aug;14(8):690-701.

9.

Targeted inhibition of mTOR signaling improves sensitivity of esophageal squamous cell carcinoma cells to cisplatin.

Hou G, Yang S, Zhou Y, Wang C, Zhao W, Lu Z.

J Immunol Res. 2014;2014:845763. doi: 10.1155/2014/845763. Epub 2014 Apr 10.

10.

Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Li SH, Huang EY, Lu HI, Huang WT, Yen CC, Huang WC, Chen CH.

J Thorac Cardiovasc Surg. 2012 Dec;144(6):1352-9, 1359.e1. doi: 10.1016/j.jtcvs.2012.06.049. Epub 2012 Jul 25.

PMID:
22841170
11.

Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma.

Hirashima K, Baba Y, Watanabe M, Karashima RI, Sato N, Imamura Y, Nagai Y, Hayashi N, Iyama KI, Baba H.

Br J Cancer. 2012 Feb 28;106(5):876-82. doi: 10.1038/bjc.2012.36. Epub 2012 Feb 14.

12.

Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.

Hirasawa T, Miyazawa M, Yasuda M, Shida M, Ikeda M, Kajiwara H, Matsui N, Fujita M, Muramatsu T, Mikami M.

Int J Gynecol Cancer. 2013 Sep;23(7):1210-8. doi: 10.1097/IGC.0b013e31829d2d51.

PMID:
23899586
13.

mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.

Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S.

PLoS One. 2013 May 14;8(5):e62104. doi: 10.1371/journal.pone.0062104. Print 2013.

14.
15.

The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.

Bozec A, Etienne-Grimaldi MC, Fischel JL, Sudaka A, Toussan N, Formento P, Milano G.

Oral Oncol. 2011 May;47(5):340-4. doi: 10.1016/j.oraloncology.2011.02.020. Epub 2011 Mar 21.

PMID:
21421338
16.

Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma.

Hirashima K, Baba Y, Watanabe M, Karashima R, Sato N, Imamura Y, Hiyoshi Y, Nagai Y, Hayashi N, Iyama K, Baba H.

Ann Surg Oncol. 2010 Sep;17(9):2486-93. doi: 10.1245/s10434-010-1040-1. Epub 2010 Mar 26.

PMID:
20339946
17.

Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.

Ingels A, Zhao H, Thong AE, Saar M, Valta MP, Nolley R, Santos J, Peehl DM.

Int J Cancer. 2014 May 15;134(10):2322-9. doi: 10.1002/ijc.28579. Epub 2013 Nov 18.

18.

The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.

Zhao H, Cui K, Nie F, Wang L, Brandl MB, Jin G, Li F, Mao Y, Xue Z, Rodriguez A, Chang J, Wong ST.

Breast Cancer Res Treat. 2012 Jan;131(2):425-36. doi: 10.1007/s10549-011-1420-7. Epub 2011 Mar 11.

PMID:
21394501
19.

Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy.

Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX, Chen SJ, Chen Y, Zhao WL.

Cell Death Dis. 2012 Mar 1;3:e275. doi: 10.1038/cddis.2012.13.

20.

Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.

Moriya M, Yamada T, Tamura M, Ishikawa D, Hoda MA, Matsumoto I, Klepetko W, Oda M, Yano S, Watanabe G.

Oncol Rep. 2014 Mar;31(3):1109-15. doi: 10.3892/or.2013.2948. Epub 2013 Dec 30.

PMID:
24378576
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk